Study 20 of 20Tirzepatide literatureThe lancet. Diabetes & endocrinologyTop journal2026
From adiposity to multisystem morbidity: the case for weight loss as disease modification.
Not reported in abstract.
Where it sits
this study against the rest of the tirzepatide corpus3
Preclinical · this one
12
Observational
1
Open-label
2
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Tirzepatide corpus
AInsights from a double-blind, randomized, direct-to-participant intervention trial for Long COVIDbiorxiv-preprint · 2026 · 1,058 participants enrolled in 73 days.HumanBEvaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.The Journal of clinical endocrinology and metabolism · 2026 · Body weight reduced from 91.0 kg (IQR 75.0 - 106.0) to 82.8 kg (IQR 69.0 - 93.4; p<0.0001).HumanAClinical performance of monolithic and veneered zirconia three-unit posterior FDPs: A five-year multicenter randomized controlled trial.Journal of dentistry · 2026 · Survival at 5 years was 94.7% for MONO-FDPs, 100% for FV-FDPs, and 100% for PV-FDPs.HumanBTirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.BMJ (Clinical research ed.) · 2026HumanBEarly changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.Nutrition (Burbank, Los Angeles County, Calif.) · 2026 · n=51 · Body weight decreased by 8.75 kg (-8.18%, P < 0.001)HumanDTirzepatide and cardiovascular outcomes.BMJ (Clinical research ed.) · 2026—